Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.72 |
| ▸ | MET | P08581 | 5/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.72 |
| ▸ | FLT3 | P36888 | 4/20 | 0.72 |
| ▸ | KDR | P35968 | 11/20 | 0.63 |
| ▸ | AXL | P30530 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067810 | 0.91 | CSF1R (0.73) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL5063899 | 0.90 | CSF1R (0.76) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL2901209 | 0.89 | CSF1R (0.70) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL574103 | 0.87 | CSF1R (0.62) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL3811087 | 0.87 | CSF1R (0.62) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL574230 | 0.86 | CSF1R (0.61) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL573993 | 0.86 | CSF1R (0.61) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL573919 | 0.85 | CSF1R (0.60) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL573851 | 0.85 | CSF1R (0.60) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL2926674 | 0.85 | AXL (0.55) | CSF1RMETPDGFRBPDGFRAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | CSF1R 80/4885MET 4/4885PDGFRB 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.